ROS Therapeutics Holding ApS: Financial statements 2025
CVR: 39507056
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
ROS Therapeutics Holding ApS (CVR 39507056) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -10,750 and a net result of DKK -26,512 compared with DKK -14,342 the year before. Equity in the 2025 report amounted to DKK -116,804.
- Gross Profit
- DKK -10,750
- Profit/Loss
- DKK -26,512
- Equity
- DKK -116,804
- Total Assets
- DKK 39,877
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -11K | -27K | -117K | 0 |
| 2024 | - | -13K | -14K | -256K | 1 |
| 2023 | - | -13K | -14K | -243K | 1 |
| 2022 | - | -13K | -14K | -229K | 1 |
| 2021 | - | -13K | -4.3M | -225K | 1 |
Official annual report
How creditworthy is ROS Therapeutics Holding ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of September 11, 2025, HDJ & LEJ Invest ApS is registered as an owner of ROS Therapeutics Holding ApS with an ownership share of 90%.
ROS Therapeutics Holding ApS has published its annual report for 2024. Gross profit came to DKK -12,875, and the net result was DKK -14,342.
About ROS Therapeutics Holding ApS
ROS Therapeutics Holding ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Hanne Damgaard Jensen. The company is owned by SPORCON LIFESCIENCE ADVISORS ApS and HDJ & LEJ Invest ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -10,750 and a net result of DKK -26,512 compared with DKK -14,342 the year before. Equity in the 2025 report amounted to DKK -116,804.
